D
Désirée van der Heijde
Researcher at Leiden University Medical Center
Publications - 764
Citations - 57315
Désirée van der Heijde is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Ankylosing spondylitis & Medicine. The author has an hindex of 107, co-authored 674 publications receiving 48488 citations. Previous affiliations of Désirée van der Heijde include Leiden University & Radboud University Nijmegen.
Papers
More filters
Journal ArticleDOI
Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis
Elisabeth Lie,Désirée van der Heijde,Till Uhlig,Marte Schrumpf Heiberg,Wenche Koldingsnes,Erik Rødevand,Cecilie Kaufmann,Knut Mikkelsen,Tore K Kvien +8 more
TL;DR: MTX treatment was associated with improvement in disease activity and health-related quality of life in patients with PsA after 6 months of treatment and two-year retention rates of MTX were similar in PsA and RA.
Journal ArticleDOI
Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study
Karen Minde Fagerli,Elisabeth Lie,Désirée van der Heijde,Marte Schrumpf Heiberg,Synøve Kalstad,Erik Rødevand,Knut Mikkelsen,Åse Stavland Lexberg,Tore K Kvien +8 more
TL;DR: Twenty–40% of patients had a response on a second TNFi after having failed one TNFi in this LOS, and this observation highlights the need for treatments with other mechanisms of action than TNF inhibition in patients with PsA.
Journal ArticleDOI
Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy.
TL;DR: Patients with active AS despite conventional therapy have significantly reduced HRQOL across a wide range of domains, and treatment with etanercept therapy significantly improves patientHRQOL, indicating that decrements in HRZOL due to AS may be at least partly reversible.
Journal ArticleDOI
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Jürgen Braun,Xenofon Baraliakos,Kay-Geert A. Hermann,Atul Deodhar,Désirée van der Heijde,Robert D. Inman,A. Beutler,Yiying Zhou,Stephen Xu,Benjamin Hsu +9 more
TL;DR: The radiographic progression rate remained stable at years 2 and 4, suggesting no acceleration of new bone formation over time in patients with ankylosing spondylitis receiving two different doses of the tumour necrosis factor antagonist golimumab.
Journal ArticleDOI
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index
Roy Fleischmann,Désirée van der Heijde,Andrew S Koenig,Ronald Pedersen,Annette Szumski,Lisa Marshall,Eustratios Bananis +6 more
TL;DR: DAS28-CRP underestimates disease activity when using cut-off points validated for DAS 28-ESR; therefore, DAS28 -ESR cut-offs should not be applied to DAS24-CRp.